Strong domestic drug production a security guarantee for Latvia in emergencies

Juris Hmeļņickis emphasizes that robust domestic pharmaceutical production is a key security guarantee for Latvia, especially during emergencies. He argues that the sector should be a strategic priority for national development, capable of competing on global markets while simultaneously generating added value within Latvia. This focus is essential for preventing potential medication shortages and safeguarding citizens' fundamental right to healthcare.

Hmeļņickis highlights the industry's dual role: bolstering national resilience and contributing to economic growth. By strengthening local manufacturing, Latvia can ensure a stable supply of essential medicines, reducing reliance on imports that could be disrupted during crises. This strategic imperative allows the country to better manage health emergencies and maintain public well-being.

The current state of Latvia's pharmaceutical industry in the global context is under review, with a clear call for accelerated development. Key tasks remain to further enhance the sector's capabilities and competitiveness. Prioritizing local production is presented not just as an economic opportunity but as a vital component of national security, ensuring that basic healthcare needs are met even under challenging circumstances.